About this trial
Cancer care for head and neck cancers is multidisciplinary and complex and knowledge on the rare ones is limited. There is a wide consensus that to support clinical research on rare cancers, clinical registries should be developed within networks specializing in rare cancers. Our hypothesis is that our head and neck cancer registry established in the framework of the European reference network on rare adults solid cancers will help to: describe the natural history of rare head and neck cancers; evaluate factors that influence prognosis; assess treatment effectiveness; measure indicators of quality of care.
The registry is a prospective observational real-world registry. It collects data from already available registries/database and/or directly from expert health care providers (HCP). Information are prospectively collected on patient characteristics; exposure, outcomes and potential confounders (https://euracan.eu/research/starter/rare-head-and-neck-cancer-registry/#codebook).
The registry if federated (i.e. data are stored by the data provider). Analyses will be performed using the federated learning approach which split computations into a local part and a central part. The data providers will share sub-computations only. Data quality checks are envisioned to assess whether data value are present, valid and believable. Validity and plausibility checks are embedded in the electronic case report form (CRF) in the form of alerts and errors during the data input. Additional checks are implemented in R and run using the federated learning to ensure a central data quality monitoring. The data analyses will include descriptive statistics showing frequency and patterns of patients' and cancers' variables; analytical analyses investigating the association of patients/disease and/or treatment characteristics and health outcomes.
Fondazione IRCCS Istituto Nazionale dei Tumori (INT) is the coordinator of the EURACAN registry as well as a data provider. At the INT, and at each HCP involved, responsible investigators ensure that the EURACAN registry will be implemented in compliance with the protocol, following the instructions and procedures described herein. Each HCP is a controller and will identify a data processor. The processing of patients' personal data taking part in the registry is compliant with local privacy legislation and the General Data Protection Regulation 2016/679 of the EU.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Patients with epithelial tumours of nasopharynx; nasal cavity and paranasal sinuses; salivary gland cancer in large and small salivary glands; and middle ear (i.e. squamous carcinoma; adenocarcinoma; neuroendocrine; adenosquamous carcinoma, teratocarcinosarcoma, NUT carcinoma, odontogenic tumors) + neuroendocrine and adenocarcinoma in hypopharynx; oropharynx; larynx; oral cavity and lip + odontogenic carcinoma in oral cavity.
Adult patients (aged ≥18 years).
Diagnosis performed or verified by the expert centre entering the patient information in the registry.
Patients entering the HCP at any clinical phase of the disease (diagnosis, treatment of primary cancer, treatment of recurrence, treatment of M+ etc.). The HCP can decide, based on its resources, the number of patients on whom it can collect data.
Disqualifiers
None
Trial population
It is an hospital based registry thus, hospitals experts in head and neck cancer. This registry won't select a sample of patients, but it will include every accordant patient present in each facility.
Trial design
Cohort
Prospective
Treatments tested in this trial
observation
Other interventionNot applicable, it is an observational registry
Treatment groups
Trial outcomes
Primary outcomes
Overall survival
The length of time from either the date of diagnosis or the start of treatment for a disease, such as cancer, that patients diagnosed with the disease are still alive
Disease free survival
The length of time after primary treatment for a cancer ends that the patient survives without any signs or symptoms of that cancer.
The percentage of patients whose cancer shrinks or disappears after treatment. Treatment response expressed as a complete response; partial response; stable disease; progression based on clinical judgment on imaging.
A change related to treatment
Incidence of cancer treatment adverse events as assessed by Common Terminology Criteria for Adverse Events (CTCAE)
Any unexpected medical problem that happens during treatment with a drug or other therapy.
Sponsors and contacts
Click on the lead sponsor to view all of their trials.
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Lead sponsor
Associazione Italiana Oncologia Cervico Cefalica
Collaborator
Ministry of Health, Italy
Collaborator
European Union
Collaborator
Alleanza Contro il Cancro
Collaborator